Silva M, Matthews ML, Jarvis C, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007;29(2):253–60. https://doi.org/10.1016/j.clinthera.2007.02.008.

CAS  Article  PubMed  Google Scholar 

SEARCH Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med. 2008;359(8):789–799. https://doi.org/10.1056/NEJMoa0801936.

Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289(13):1681–90. https://doi.org/10.1001/jama.289.13.1681.

CAS  Article  PubMed  Google Scholar 

Franc S, Dejager S, Bruckert E, Chauvenet M, Giral P, Turpin G. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther. 2003;17(5–6):459–65. https://doi.org/10.1023/b:card.0000015861.26111.ab.

CAS  Article  PubMed  Google Scholar 

Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation. 2002;106(8):1024–8. https://doi.org/10.1161/01.cir.0000032466.44170.44.

Article  PubMed  Google Scholar 

Catapano AL. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin. Curr Vasc Pharmacol. 2012;10(2):257–67. https://doi.org/10.2174/157016112799305021.

CAS  Article  PubMed  Google Scholar 

Taylor BA, Thompson PD. Statin-associated muscle disease: advances in diagnosis and management. Neurotherapeutics. 2018;15(4):1006–17. https://doi.org/10.1007/s13311-018-0670-z.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Kuncl RW. Agents and mechanisms of toxic myopathy. Curr Opin Neurol. 2009;22(5):506–15. https://doi.org/10.1097/WCO.0b013e32833045a0.

CAS  Article  PubMed  Google Scholar 

Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005;165(22):2671–6. https://doi.org/10.1001/archinte.165.22.2671.

Article  PubMed  Google Scholar 

Meriggioli MN, Barboi AC, Rowin J, Cochran EJ. HMG-CoA reductase inhibitor myopathy: clinical, electrophysiological, and pathologic data in five patients. J Clin Neuromuscul Dis. 2001;2(3):129–34.

CAS  Article  Google Scholar 

de Almeida DF, Lissa TV, Melo AC Jr. Myotonic potentials in statin-induced rhabdomyolysis. Arq Neuropsiquiatr. 2008;66(4):891–3. https://doi.org/10.1590/s0004-282x2008000600024.

Article  PubMed  Google Scholar 

Floyd JS, Brody JA, Tiniakou E, et al. Absence of anti-HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy. Muscle Nerve. 2016;54(1):142–4. https://doi.org/10.1002/mus.25127.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Mammen AL, Pak K, Williams EK, et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken). 2012;64(2):269–72. https://doi.org/10.1002/acr.20662.

CAS  Article  Google Scholar 

Mammen AL, Tiniakou E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med. 2015;373(17):1680–2. https://doi.org/10.1056/NEJMc1506163.

Article  PubMed  PubMed Central  Google Scholar 

Allenbach Y, Mammen AL, Benveniste O, et al. 224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October 2016. Neuromuscul Disord. 2018;28(1):87–99. https://doi.org/10.1016/j.nmd.2017.09.016.

Article  PubMed  Google Scholar 

McGrath ER, Doughty CT, Amato AA. Autoimmune myopathies: updates on evaluation and treatment. Neurotherapeutics. 2018;15(4):976–94. https://doi.org/10.1007/s13311-018-00676-2.

Article  PubMed  PubMed Central  Google Scholar 

Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. Am J Cardiol. 2004;94(7):935–8. https://doi.org/10.1016/j.amjcard.2004.06.033.

CAS  Article  PubMed  Google Scholar 

Litin SC, Anderson CF. Nicotinic acid-associated myopathy: a report of three cases. Am J Med. 1989;86(4):481–3. https://doi.org/10.1016/0002-9343(89)90352-5.

CAS  Article  PubMed  Google Scholar 

Slim H, Thompson PD. Ezetimibe-related myopathy: a systematic review. J Clin Lipidol. 2008;2(5):328–34. https://doi.org/10.1016/j.jacl.2008.08.430.

Article  PubMed  Google Scholar 

Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 1990;264(1):71–5. https://doi.org/10.1001/jama.1990.03450010075034.

CAS  Article  PubMed  Google Scholar 

Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580–90. https://doi.org/10.1001/jama.2016.3608.

CAS  Article  PubMed  Google Scholar 

Tiniakou E, Rivera E, Mammen AL, Christopher‐Stine L. Use of proprotein convertase subtilisin/kexin type 9 inhibitors in statin-associated immune-mediated necrotizing myopathy: a case series. Arthritis Rheumatol 2019;71(10):1723–1726. https://doi.org/10.1002/art.40919.

Kosmas CE, Muñoz Estrella A, Skavdis A, Peña Genao E, Martinez I, Guzman E. Inclisiran for the treatment of cardiovascular disease: a short review on the emerging data and therapeutic potential. Ther Clin Risk Manag. 2020;16:1031–7. https://doi.org/10.2147/TCRM.S230592.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Ruzieh M, Moroi MK, Aboujamous NM, et al. Meta-analysis comparing the relative risk of adverse events for amiodarone versus placebo. Am J Cardiol. 2019;124(12):1889–93. https://doi.org/10.1016/j.amjcard.2019.09.008.

CAS  Article  PubMed  Google Scholar 

Pulipaka U, Lacomis D, Omalu B. Amiodarone-induced neuromyopathy: three cases and a review of the literature. J Clin Neuromuscul Dis. 2002;3(3):97–105. https://doi.org/10.1097/00131402-200203000-00001.

Article  PubMed  Google Scholar 

Alsheikh-Ali AA, Karas RH. Adverse events with concomitant amiodarone and statin therapy. Prev Cardiol. 2005;8(2):95–7. https://doi.org/10.1111/j.1520-037x.2005.4060.x.

CAS  Article  PubMed  Google Scholar 

Ledingham D, Cordato D. Focal myositis and contracture secondary to amiodarone extravasation from a peripheral cannula. BMJ Case Rep 2019;12(1):bcr-2018–227725. https://doi.org/10.1136/bcr-2018-227725.

Venkayya RV, Poole RM, Pentz WH. Respiratory failure from procainamide-induced myopathy. Ann Intern Med. 1993;119(4):345–6. https://doi.org/10.7326/0003-4819-119-4-199308150-00026.

CAS  Article  PubMed  Google Scholar 

Lewis CA, Boheimer N, Rose P, Jackson G. Myopathy after short term administration of procainamide. Br Med J (Clin Res Ed). 1986;292(6520):593–4. https://doi.org/10.1136/bmj.292.6520.593.

CAS  Article  Google Scholar 

Fontiveros ES, Cumming WJ, Hudgson P. Procainamide-induced myositis. J Neurol Sci. 1980;45(1):143–7. https://doi.org/10.1016/s0022-510x(80)80016-5.

CAS  Article  PubMed  Google Scholar 

Teicher A, Rosenthal T, Kissin E, Sarova I. Labetalol-induced toxic myopathy. Br Med J (Clin Res Ed). 1981;282(6279):1824–5. https://doi.org/10.1136/bmj.282.6279.1824.

CAS  Article  Google Scholar 

Willis JK, Tilton AH, Harkin JC, Boineau FG. Reversible myopathy due to labetalol. Pediatr Neurol. 1990;6(4):275–6. https://doi.org/10.1016/0887-8994(90)90122-h.

CAS  Article  PubMed  Google Scholar 

Kim YJ, Kim HR, Jeon HJ, et al. Rhabdomyolysis in a patient taking nebivolol. Kidney Res Clin Pract. 2016;35(3):182–6. https://doi.org/10.1016/j.krcp.2015.09.003.

Article  PubMed  PubMed Central  Google Scholar 

Notturno F, Uncini A. Association of rhabdomyolysis with nebivolol. Muscle Nerve. 2021;63(1):E1–2. https://doi.org/10.1002/mus.27078.

Article  PubMed  Google Scholar 

Arellano F, Krupp P. Muscular disorders associated with cyclosporin. Lancet. 1991;337(8746):915. https://doi.org/10.1016/0140-6736(91)90245-k.

CAS  Article  PubMed  Google Scholar 

Breil M, Chariot P. Muscle disorders associated with cyclosporine treatment. Muscle Nerve. 1999;22(12):1631–6. https://doi.org/10.1002/(sici)1097-4598(199912)22:12%3c1631::aid-mus3%3e3.0.co;2-v.

CAS  Article  PubMed  Google Scholar 

Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M. Colchicine myopathy and neuropathy. N Engl J Med. 1987;316(25):1562–8. https://doi.org/10.1056/NEJM198706183162502.

CAS  Article  PubMed  Google Scholar 

Rutkove SB, De Girolami U, Preston DC, et al. Myotonia in colchicine myoneuropathy. Muscle Nerve. 1996;19(7):870–5. https://doi.org/10.1002/(SICI)1097-4598(199607)19:7%3c870::AID-MUS9%3e3.0.CO;2-6.

CAS  Article  PubMed  Google Scholar 

Tanios MA, El Gamal H, Epstein SK, Hassoun PM. Severe respiratory muscle weakness related to long-term colchicine therapy. Respir Care. 2004;49(2):189–91.

PubMed  Google Scholar 

Amato AA, Rusell JA. Toxic Myopathies. In: Amato AA, Rusell JA, editors. Neuromuscular disorders. 2nd ed. New York: McGraw Hill Companies Inc; 2016. p. 887–910.

Google Scholar 

Caglar K, Odabasi Z, Safali M, Yenicesu M, Vural A. Colchicine-induced myopathy with myotonia in a patient with chronic renal failure. Clin Neurol Neurosurg. 2003;105(4):274–6. https://doi.org/10.1016/s0303-8467(03)00030-1.

Article  PubMed  Google Scholar 

Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and literature review. Pharmacotherapy. 2004;24(12):1784–92. https://doi.org/10.1592/phco.24.17.1784.52334.

Article  PubMed  Google Scholar 

Kwon OC, Hong S, Ghang B, Kim YG, Lee CK, Yoo B. Risk of colchicine-associated myopathy in gout: influence of concomitant use of statin. Am J Med. 2017;130(5):583–7. https://doi.org/10.1016/j.amjmed.2016.12.006.

CAS  Article